
==== Front
Amino Acids
Amino Acids
Amino Acids
0939-4451 1438-2199 Springer-Verlag Vienna 

17978889
604
10.1007/s00726-007-0604-2
Article
Computational studies of the binding modes of A2A adenosine receptor antagonists
Ye Y. 1 Wei J. 1 Dai X. 2 Gao Q. (408) 616-7210qingzhi@gmail.com 2  grid.33763.320000000417612484School of Pharmaceutical Science and Technology, Tianjin University, Tianjin, China 
 Chemistry Department, XenoPort Inc., Santa Clara, CA U.S.A. 
5 11 2007 
2008 
35 2 389 396
10 8 2007 12 9 2007 © Springer-Verlag 2007This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.Summary.
A molecular docking study was performed on several structurally diverse A2A AR antagonists, including xanthines, and non-xanthine type antagonists to investigate their binding modes with A2A adenosine receptor (AR), one of the four subtypes of AR, which is currently of great interest as a target for therapeutic intervention, in particular for Parkinson’s disease. The high-affinity binding site was found to be a hydrophobic pocket with the involvement of hydrogen bonding interactions as well as π–π stacking interactions with the ligands. The detailed binding modes for both xanthine and non-xanthine type A2A antagonists were compared and the essential features were extracted and converted to database searchable queries for virtual screening study of novel A2A AR antagonists. Findings from this study are helpful for elucidating the binding pattern of A2A AR antagonists and for the design of novel active ligands.

Keywords: Adenosine receptors – A2A AR antagonists – Binding mode – Docking – Pharmacophore – Virtual screeningissue-copyright-statement© Springer-Verlag 2008
==== Body
Authors’ address: Qingzhi Gao, Chemistry Department, XenoPort Inc., 3410 Central Expressway, Santa Clara, CA 95051, U.S.A.
==== Refs
References
Baraldi PG Cacciari B Romagnoli R Spalluto G Monopoli A Ongini E Varani K Borea PA  7-Substituted 5-amino-2-(2-furyl)pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as A2A adenosine receptor antagonists: a study on the importance of modifications at the side chain on the activity and solubility
J Med Chem 2002 45 115 126
10.1021/jm010924c 11754583 
Barbara C Giorgia P Giampiero S  Medicinal chemistry of A2A adenosine receptor antagonists
Curr Top Med Chem 2003 3 403 411
10.2174/1568026033392183 12570758 
Bockaert J Pin JP  Molecular tinkering of G protein-coupled receptors: an evolutionary success
EMBO J 1999 18 1723 1729
10.1093/emboj/18.7.1723 10202136 
Chou KC  Insights from modelling the 3D structure of the extracellular domain of alpha7 nicotinic acetylcholine receptor
Biochem Biophys Res Commun 2004a 319 433 438
10.1016/j.bbrc.2004.05.016 15178425 
Chou KC  Insights from modelling the tertiary structure of BACE2
J Proteome Res 2004b 3 1069 1072
10.1021/pr049905s 15473697 
Chou KC  Modelling extracellular domains of GABA-A receptors: subtypes 1, 2, 3, and 5
Biochem Biophys Res Commun 2004c 316 636 642
10.1016/j.bbrc.2004.02.098 15033447 
Chou KC  Molecular therapeutic target for type-2 diabetes
J Proteome Res 2004d 3 1284 1288
10.1021/pr049849v 15595739 
Chou KC  Review: structural bioinformatics and its impact to biomedical science
Curr Med Chem 2004e 11 2105 2134
15279552 
Chou KC  Coupling interaction between thromboxane A2 receptor and alpha-13 subunit of guanine nucleotide-binding protein
J Proteome Res 2005a 4 1681 1686
10.1021/pr050145a 16212421 
Chou KC  Modeling the tertiary structure of human cathepsin-E
Biochem Biophys Res Commun 2005b 331 56 60
10.1016/j.bbrc.2005.03.123 15845357 
Chou KC  Atta-ur-Rahman Reitz AB  Structural bioinformatics and its impact to biomedical science and drug discovery
Frontiers in medicinal chemistry 2006 The Netherlands Bentham Science Publishers 455 502

Chou KC Tomasselli AG Heinrikson RL  Prediction of the tertiary structure of a caspase-9/inhibitor complex
FEBS Lett 2000 470 249 256
10.1016/S0014-5793(00)01333-8 10745077 
Chou KC Watenpaugh KD Heinrikson RL  A model of the complex between cyclin-dependent kinase 5(Cdk5) and the activation domain of neuronal Cdk5 activator
Biochem Biophys Res Commun 1999 259 420 428
10.1006/bbrc.1999.0792 10362524 
Chou KC Wei DQ Du QS Sirois S Zhong WZ  Review: progress in computational approach to drug development against SARS
Curr Med Chem 2006 13 3263 3270
10.2174/092986706778773077 17168850 
Chou KC Wei DQ Zhong WZ  Binding mechanism of coronavirus main proteinase with ligands and its implication to drug design against SARS
Biochem Biophys Res Commun 2003 308 148 151
10.1016/S0006-291X(03)01342-1 12890493 
Du QS Wang S Wei DQ Sirois S Chou KC  Molecular modelling and chemical modification for finding peptide inhibitor against SARS CoV Mpro
Anal Biochem 2005a 337 262 270
10.1016/j.ab.2004.10.003 15691506 
Du QS Wang SQ Jiang ZQ Gao WN Li YD Wei DQ Chou KC  Application of bioinformatics in search for cleavable peptides of SARS-CoV Mpro and chemical modification of octapeptides
Med Chem 2005b 1 209 213
10.2174/1573406053765468 16787316 
Du QS Wang SQ Wei DQ Zhu Y Guo H Sirois S Chou KC  Polyprotein cleavage mechanism of SARS CoV Mpro and chemical modification of octapeptide
Peptides 2004 25 1857 1864
10.1016/j.peptides.2004.06.018 15501516 
Du QS Sun H Chou KC  Inhibitor design for SARS coronavirus main protease based on “distorted key theory”
Med Chem 2007a 3 1 6
10.2174/157340607779317616 17266617 
Du QS, Wang SQ, Chou KC (2007b) Analogue inhibitors by modifying oseltamivir based on the crystal neuraminidase structure for treating drug-resistant H5N1 virus. Biochem Biophys Res Commun; doi: 10.1016/j.bbrc.2007.08.025
Elenkov IJ Chrousos GP Wilder RL  Neuroendocrine regulation of IL-2 and TNF-alpha/IL-10 balance, clinical implications
Ann NY Acad Sci 2000 917 94 105
10.1111/j.1749-6632.2000.tb05374.x 11268424 
Feokistov I Biaggioni I  Pharmalogical characterization of adenosine A2B receptors
Biochem Pharmacol 1998 55 627 633
10.1016/S0006-2952(97)00512-1 9515573 
Fredholm BB IJzerman AP Jacobson KA Klotz KN Linden J  International union of pharmacology, XXV. Nomenclature and classification of adenosine receptors
Pharmacol Rev 2001 53 527 552
11734617 
Gao WN Wei DQ Li Y Gao H Xu WR Li AX Chou KC  Agaritine and its derivatives are potential inhibitors against HIV proteases
Med Chem 2007 3 221 226
10.2174/157340607780620644 17504192 
Gui XL, Li L, Wei DQ, Zhu YS, Chou KC (2007) Cleavage mechanism of the H5N1 hemagglutinin by trypsin and furin. Amino Acids (in press)
Hourani SM Boon K Fooks HM Prentice DJ  Role of cyclic nucleotides in vasodilations of the rat thoracic aorta induced by adenosine analogues
Br J Pharmacol 2001 133 833 840
10.1038/sj.bjp.0704140 11454656 
Ivanov AA Baskin II Palyulin VA Piccagli L Baraldi PG Zefirov NS  Molecular modeling and molecular dynamics simulation of the human A2B adenosine receptor. The study of the possible binding modes of the A2B receptor antagonists
J Med Chem 2005 48 6813 6820
10.1021/jm049418o 16250640 
Ivanov AA Baskin II Palyulin VA Zefirov NS  Molecular modeling the human A1 adenosine receptor and study of the mechanisms of its selective ligand binding
Dokl Biochem Biophys 2002 386 271 274
10.1023/A:1020715812906 12469507 
Ivanov AA Baskin II Palyulin VA Zefirov NS  Molecular modeling of the human A2A adenosine receptor
Dokl Biochem Biophys 2003 389 94 97
10.1023/A:1023632005607 12856413 
Kim J Wess J van Rhee AM Schöneberg T Jacobson KA  Site-directed mutagenesis identifies residues involved into ligand recognition in the human A2A adenosine receptor
J Biol Chem 1995 270 13987 13997
10.1074/jbc.270.23.13987 7775460 
Knutsen LJ Weiss SM  kw-6002 (Kyowa Hakko Kogyo)
Curr Opin Invest Drugs 2001 2 668 673

Li L Wei DQ Wang JF Chou KC  Computational studies of the binding mechanism of calmodulin with chrysin
Biochem Biophys Res Commun 2007 358 1102 1107
10.1016/j.bbrc.2007.05.053 17521610 
Matasi JJ Caldwell JP Hao J Neustadt B Arik L Foster CJ Lachowicz J Tulshian DB  The discovery and synthesis of novel adenosine receptor (A2A) antagonists
Bioorg Med Chem Lett 2005 15 1333 1336
10.1016/j.bmcl.2005.01.019 15713381 
Müller CE Geis U Hipp J Schobert U Frobenius W Pawlowski M Suzuki F Sandoval-Ramírez J  Synthesis and structure-activity relationship of 3,7-dimethyl-1-propargylxanthine derivatives, A2A-selective adenosine receptor antagonists
J Med Chem 1997 40 4396 4405
10.1021/jm970515+ 9435909 
Müller CE Sandoval-Ramírez J Schobert U Geis U Frobenius W Klotz K  N,8-(Sulfostyryl)xanthines: water-soluble A2A-selective adenosine receptor antagonists
Bioorg Med Chem 1998 6 707 719
10.1016/S0968-0896(98)00025-X 9681137 
Nonaka Y Shimada J Nonaka H Koike N Aoki N Kobayashi H Kase H Yamaguchi K Suzuki F  Photoisomerization of a potent and selective adenosine A2 antagonist, (E)-1,3-dipropyl-8-(3,4-dimethoxystyryl)-7-methylxanthine
J Med Chem 1993 36 3731 3733
10.1021/jm00075a031 8246243 
Ongini E Adami M Ferri C Bertorelli R  Adenosine A2A receptors and neuroprotection
Ann NY Acad Sci 1997 825 30 48
10.1111/j.1749-6632.1997.tb48412.x 9369973 
Richardson PJ Kase H Jenner PG  Adenosine A2A receptor antagonists as new agents for the treatment of Parkinson’s disease
Trends Pharmacol Sci 1997 18 338 344
9345853 
Sauer R Maurinsh J Reith U Fülle F Klotz KN Müller CE  Water-soluble phosphate prodrugs of 1-propargyl-8-styrylxanthine derivatives, A2A-selective adenosine receptor antagonists
J Med Chem 2000 43 440 448
10.1021/jm9911480 10669571 
Sirois S Wei DQ Du QS Chou KC  Virtual screening for SARS-CoV protease based on KZ7088 pharmacophore points
J Chem Inf Comput Sci 2004 44 1111 1122
10.1021/ci034270n 15154780 
Stefano M Giampiero S Kenneth AJ  Techniques: recent developments in computer-aided engineering of GPCR ligands using the human adenosine A3 receptor as an example
Trends Pharmacol Sci 2005 25 44 51

Vassalo R Lipsky JJ  Theophylline: recent advances in the understanding of its mode of action and uses in clinical practice
Mayo Clin Proc 1998 73 346 354
10.4065/73.4.346 9559039 
Varani K Rigamonti D Sipione S Camurri A Borea PA Cattabeni F Abbracchio MP Cattaneo E  Aberrant amplification of A2A receptor signaling in striatal cells expressing mutant huntingtin
FASEB 2001 15 1245 1247

Vu CB Peng B Kumaravel G Smits G Jin X Phadke D Engber T Huang C Reilly J Tam S Grant D Hetu G Chen L Zhang J Petter RC  Piperazine derivatives of [1,2,4]triazolo-[1,5-a][1,3,5] triazine as potent and selective adenosine A2A receptor antagonists
J Med Chem 2004a 47 4291 4299
10.1021/jm0498405 15294001 
Vu CB Shields P Peng B Kumaravel G Jin X Phadke D Wang J Engber T Ayyub E Petter RC  Triamino derivatives of triazolotriazine and triazolopyrimidine as adenosine A2a receptor antagonists
Bioorg Med Chem Lett 2004b 14 4835 4838
10.1016/j.bmcl.2004.07.048 15341934 
Wang JF Wei DQ Li L Zheng SY Li YX Chou KC  3D Structure modeling of cytochrome P450 2C19 and its implication for personalized drug design
Biochem Biophys Res Commun 2007a 355 513 519
10.1016/j.bbrc.2007.01.185 17307149 
Wang JF Wei DQ Lin Y Wang YH Du HL Li YX Chou KC  Insights from modeling the 3D structure of NAD(P)H-dependent D-xylose reductase of Pichia stipitis and its binding interactions with NAD and NADP
Biochem Biophys Res Commun 2007b 359 323 329
10.1016/j.bbrc.2007.05.101 17544374 
Wang SQ Du QS Chou KC  Study of drug resistance of chicken influenza A virus (H5N1) from homology-modeled 3D structures of neuraminidases
Biochem Biophys Res Commun 2007c 354 634 640
10.1016/j.bbrc.2006.12.235 17266937 
Wang SQ Du QS Zhao K Li AX Wei DQ Chou KC  Virtual screening for finding natural inhibitor against cathepsin-L for SARS therapy
Amino Acids 2007d 33 129 135
10.1007/s00726-006-0403-1 16998715 
Wei DQ Sirois S Du QS Arias HR Chou KC  Theoretical studies of Alzheimer’s disease drug candidate [(2,4-dimethoxy) benzylidene]-anabaseine dihydrochloride (GTS-21) and its derivatives
Biochem Biophys Res Commun 2005 338 1059 1064
10.1016/j.bbrc.2005.10.047 16256952 
Wei DQ Du QS Sun H Chou KC  Insights from modeling the 3D structure of H5N1 influenza virus neuraminidase and its binding interactions with ligands
Biochem Biophys Res Commun 2006a 344 1048 1055
10.1016/j.bbrc.2006.03.210 16647045 
Wei DQ Zhang R Du QS Gao WN Li Y Gao H Wang SQ Zhang X Li AX Sirois S Chou KC  Anti-SARS drug screening by molecular docking
Amino Acids 2006b 31 73 80
10.1007/s00726-006-0361-7 16715412 
Wei H Zhang R Wang C Zheng H Chou KC Wei DQ  Molecular insights of SAH enzyme catalysis and their implication for inhibitor design
J Theor Biol 2007 244 692 702
10.1016/j.jtbi.2006.09.011 17069857 
Wei J Wang S Gao S Dai X Gao Q  3D-Pharmacophore models for selective A2A and A2B adenosine receptor antagonists
J Chem Inf Model 2007 47 2 613 625
10.1021/ci600410m 17330954 
Zhang R Wei DQ Du QS Chou KC  Molecular modeling studies of peptide drug candidates against SARS
Med Chem 2006 2 309 314
10.2174/157340606776930736 16948478

